{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T16:15:45Z","timestamp":1776010545710,"version":"3.50.1"},"publisher-location":"Berlin, Heidelberg","reference-count":33,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783662586136","type":"print"},{"value":"9783662586143","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/8904_2018_113","type":"book-chapter","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T10:32:20Z","timestamp":1529404340000},"page":"117-124","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Short-Term Administration of Mycophenolate Is Well-Tolerated in CLN3 Disease (Juvenile Neuronal Ceroid Lipofuscinosis)"],"prefix":"10.1007","author":[{"given":"Erika F.","family":"Augustine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher A.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather R.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Defendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Vierhile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"Timm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill M.","family":"Weimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan W.","family":"Mink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick J.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,20]]},"reference":[{"issue":"9","key":"113_CR1","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1177\/0883073813494813","volume":"28","author":"HR Adams","year":"2013","unstructured":"Adams HR, Mink JW (2013) Neurobehavioral features and natural history of juvenile neuronal ceroid lipofuscinosis (Batten disease). J Child Neurol 28(9):1128\u20131136. https:\/\/doi.org\/10.1177\/0883073813494813","journal-title":"J Child Neurol"},{"issue":"Suppl 1","key":"113_CR2","first-page":"655","volume":"13","author":"EF Augustine","year":"2016","unstructured":"Augustine EF, Mink JW (2016) Juvenile NCL (CLN3 disease): emerging disease-modifying therapeutic strategies. Pediatr Endocrinol Rev 13(Suppl 1):655\u2013662","journal-title":"Pediatr Endocrinol Rev"},{"issue":"2","key":"113_CR3","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1016\/j.ymgme.2011.11.021","volume":"105","author":"E Augustine","year":"2012","unstructured":"Augustine E, Newhouse N, Adams H, Vierhile A, Kwon J, Marshall F, Mink J (2012) Epilepsy in juvenile neuronal ceroid lipofuscinosis is usually characterized by well-controlled generalized tonic-clonic seizures. Mol Genet Metab 105(2):S18\u2013S19. https:\/\/doi.org\/10.1016\/j.ymgme.2011.11.021","journal-title":"Mol Genet Metab"},{"issue":"9","key":"113_CR4","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1177\/0883073813495959","volume":"28","author":"EF Augustine","year":"2013","unstructured":"Augustine EF, Adams HR, Mink JW (2013) Clinical trials in rare disease: challenges and opportunities. J Child Neurol 28(9):1142\u20131150. https:\/\/doi.org\/10.1177\/0883073813495959","journal-title":"J Child Neurol"},{"key":"113_CR5","doi-asserted-by":"crossref","DOI":"10.1201\/9781420036091","volume-title":"Design and analysis of cross-over trials","author":"MGK Byron Jones","year":"2003","unstructured":"Byron Jones MGK (2003) Design and analysis of cross-over trials, 2nd edn. Chapman and Hall\/CRC, Boca Raton","edition":"2"},{"key":"113_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.nbd.2007.08.007","volume":"29","author":"JA Castaneda","year":"2008","unstructured":"Castaneda JA, Pearce DA (2008) Identification of alpha-fetoprotein as an autoantigen in juvenile Batten disease. Neurobiol Dis 29:92\u2013102","journal-title":"Neurobiol Dis"},{"issue":"12","key":"113_CR7","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1093\/hmg\/11.12.1421","volume":"11","author":"S Chattopadhyay","year":"2002","unstructured":"Chattopadhyay S, Ito M, Cooper JD, Brooks AI, Curran TM, Powers JM, Pearce DA (2002a) An autoantibody inhibitory to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease. Hum Mol Genet 11(12):1421\u20131431","journal-title":"Hum Mol Genet"},{"issue":"11","key":"113_CR8","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1212\/01.WNL.0000041913.97883.8B","volume":"59","author":"S Chattopadhyay","year":"2002","unstructured":"Chattopadhyay S, Kriscenski-Perry E, Wenger DA, Pearce DA (2002b) An autoantibody to GAD65 in sera of patients with juvenile neuronal ceroid lipofuscinoses. Neurology 59(11):1816\u20131817","journal-title":"Neurology"},{"issue":"3","key":"113_CR9","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10545-011-9421-6","volume":"35","author":"J Cialone","year":"2012","unstructured":"Cialone J, Adams H, Augustine EF, Marshall FJ, Kwon JM, Newhouse N et al (2012) Females experience a more severe disease course in Batten disease. J Inherit Metab Dis 35(3):549\u2013555. https:\/\/doi.org\/10.1007\/s10545-011-9421-6","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"113_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cct.2013.04.004","volume":"35","author":"EA Blieck de","year":"2013","unstructured":"de Blieck EA, Augustine EF, Marshall FJ, Adams H, Cialone J, Dure L et al (2013) Methodology of clinical research in rare diseases: development of a research program in juvenile neuronal ceroid lipofuscinosis (JNCL) via creation of a patient registry and collaboration with patient advocates. Contemp Clin Trials 35(2):48\u201354. https:\/\/doi.org\/10.1016\/j.cct.2013.04.004","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"113_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1365-2125.2012.04305.x","volume":"75","author":"HJ Downing","year":"2013","unstructured":"Downing HJ, Pirmohamed M, Beresford MW, Smyth RL (2013) Paediatric use of mycophenolate mofetil. Br J Clin Pharmacol 75(1):45\u201359. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04305.x","journal-title":"Br J Clin Pharmacol"},{"key":"113_CR12","unstructured":"Drack A, Augustine E, Grider T, Pearce D, Mullins R (2012) Anti-retinal antibodies in Juvenile Neuronal Ceroid Lipofuscinosis (JNCL). In: Paper presented at the 13th international congress on neuronal ceroid lipofuscinoses, London"},{"issue":"4","key":"113_CR13","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1006\/mgme.1999.2815","volume":"66","author":"T Hatonen","year":"1999","unstructured":"Hatonen T, Kirveskari E, Heiskala H, Sainio K, Laakso ML, Santavuori P (1999) Melatonin ineffective in neuronal ceroid lipofuscinosis patients with fragmented or normal motor activity rhythms recorded by wrist actigraphy. Mol Genet Metab 66(4):401\u2013406. https:\/\/doi.org\/10.1006\/mgme.1999.2815","journal-title":"Mol Genet Metab"},{"key":"113_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13023-017-0597-1","volume":"12","author":"SW Hee","year":"2017","unstructured":"Hee SW, Willis A, Tudur Smith C, Day S, Miller F, Madan J et al (2017) Does the low prevalence affect the sample size of interventional clinical trials of rare diseases? An analysis of data from the aggregate analysis of clinicaltrials.gov. Orphanet J Rare Dis 12:44. https:\/\/doi.org\/10.1186\/s13023-017-0597-1","journal-title":"Orphanet J Rare Dis"},{"key":"113_CR15","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1212\/WNL.0b013e318237f649","volume":"77","author":"JM Kwon","year":"2011","unstructured":"Kwon JM, Adams H, Rothberg PG, Augustine EF, Marshall FJ, Deblieck EA et al (2011) Quantifying physical decline in juvenile neuronal ceroid lipofuscinosis (Batten disease). Neurology 77:1801\u20131807","journal-title":"Neurology"},{"issue":"6","key":"113_CR16","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/0092-8674(95)90274-0","volume":"82","author":"TJ Lerner","year":"1995","unstructured":"Lerner TJ, Boustany R-MN, Anderson JW, D\u2019Arigo KL, Schlumpf K, Buckler AJ et al (1995) Isolation of a novel gene underlying batten disease, CLN3. Cell 82(6):949\u2013957. https:\/\/doi.org\/10.1016\/0092-8674(95)90274-0","journal-title":"Cell"},{"key":"113_CR17","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1365-2990.2006.00738.x","volume":"32","author":"MJ Lim","year":"2006","unstructured":"Lim MJ, Beake J, Bible E, Curran TM, Ramirez-Montealegre D, Pearce DA, Cooper JD (2006) Distinct patterns of serum immunoreactivity as evidence for multiple brain-directed autoantibodies in juvenile neuronal ceroid lipofuscinosis. Neuropathol Appl Neurobiol 32:469\u2013482","journal-title":"Neuropathol Appl Neurobiol"},{"key":"113_CR18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.nbd.2006.09.005","volume":"25","author":"MJ Lim","year":"2007","unstructured":"Lim MJ, Alexander N, Benedict JW, Chattopadhyay S, Shemilt SJ, Guerin CJ et al (2007) IgG entry and deposition are components of the neuroimmune response in Batten disease. Neurobiol Dis 25:239\u2013251","journal-title":"Neurobiol Dis"},{"key":"113_CR19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1212\/01.wnl.0000169019.41332.8a","volume":"65","author":"FJ Marshall","year":"2005","unstructured":"Marshall FJ, de Blieck EA, Mink JW, Dure L, Adams H, Messing S et al (2005) A clinical rating scale for Batten disease: reliable and relevant for clinical trials. Neurology 65:275\u2013279","journal-title":"Neurology"},{"issue":"10","key":"113_CR20","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1177\/1352458516678474","volume":"23","author":"A Montcuquet","year":"2017","unstructured":"Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D et al (2017) Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult Scler 23(10):1377\u20131384. https:\/\/doi.org\/10.1177\/1352458516678474","journal-title":"Mult Scler"},{"key":"113_CR21","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1212\/WNL.0b013e31821435bd","volume":"76","author":"JR Ostergaard","year":"2011","unstructured":"Ostergaard JR, Rasmussen TB, Molgaard H (2011) Cardiac involvement in juvenile neuronal ceroid lipofuscinosis (Batten disease). Neurology 76:1245\u20131251","journal-title":"Neurology"},{"key":"113_CR22","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1212\/01.WNL.0000145836.72059.3B","volume":"63","author":"DA Pearce","year":"2004","unstructured":"Pearce DA, Atkinson M, Tagle DA (2004) Glutamic acid decarboxylase autoimmunity in Batten disease and other disorders. Neurology 63:2001\u20132005","journal-title":"Neurology"},{"issue":"1","key":"113_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2307\/2346652","volume":"30","author":"RJ Prescott","year":"1981","unstructured":"Prescott RJ (1981) The comparison of success rates in cross-over trials in the presence of an order effect. J R Stat Soc Ser C (Appl Stat) 30(1):9\u201315. https:\/\/doi.org\/10.2307\/2346652","journal-title":"J R Stat Soc Ser C (Appl Stat)"},{"issue":"4","key":"113_CR24","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1212\/01.wnl.0000151973.08426.7e","volume":"64","author":"D Ramirez-Montealegre","year":"2005","unstructured":"Ramirez-Montealegre D, Chattopadhyay S, Curran TM, Wasserfall C, Pritchard L, Schatz D et al (2005) Autoimmunity to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease. Neurology 64(4):743\u2013745. https:\/\/doi.org\/10.1212\/01.wnl.0000151973.08426.7e","journal-title":"Neurology"},{"issue":"4","key":"113_CR25","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1055\/s-0028-1091529","volume":"8","author":"P Santavuori","year":"1977","unstructured":"Santavuori P, Moren R (1977) Experience of antioxidant treatment in neuronal ceroid-lipofuscinosis of Spielmeyer-Sjogren type. Neuropadiatrie 8(4):333\u2013344. https:\/\/doi.org\/10.1055\/s-0028-1091529","journal-title":"Neuropadiatrie"},{"issue":"2","key":"113_CR26","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1600-0404.1985.tb03178.x","volume":"71","author":"P Santavuori","year":"1985","unstructured":"Santavuori P, Westermarck T, Rapola J, Pohja P, Moren R, Lappi M, Vuonnala U (1985) Antioxidant treatment in Spielmeyer-Sjogren\u2019s disease. Acta Neurol Scand 71(2):136\u2013145","journal-title":"Acta Neurol Scand"},{"key":"113_CR27","first-page":"273","volume":"266","author":"P Santavuori","year":"1989","unstructured":"Santavuori P, Heiskala H, Autti T, Johansson E, Westermarck T (1989) Comparison of the clinical courses in patients with juvenile neuronal ceroid lipofuscinosis receiving antioxidant treatment and those without antioxidant treatment. Adv Exp Med Biol 266:273\u2013282","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"113_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154285","volume":"11","author":"S Sato","year":"2016","unstructured":"Sato S, Murakami A, Kuwajima A, Takehara K, Mimori T, Kawakami A et al (2016) Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies. PLoS One 11(4):e0154285. https:\/\/doi.org\/10.1371\/journal.pone.0154285","journal-title":"PLoS One"},{"key":"113_CR29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jneuroim.2010.08.024","volume":"230","author":"SS Seehafer","year":"2011","unstructured":"Seehafer SS, Ramirez-Montealegre D, Wong AM, Chan CH, Castaneda J, Horak M et al (2011) Immunosuppression alters disease severity in juvenile Batten disease mice. J Neuroimmunol 230:169\u2013172 Netherlands: 2010 Elsevier B.V.","journal-title":"J Neuroimmunol"},{"key":"113_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/0470854596","volume-title":"Cross-over trials in clinical research","author":"S Senn","year":"2002","unstructured":"Senn S (2002) Cross-over trials in clinical research, 2nd edn. Wiley, New York","edition":"2"},{"issue":"6","key":"113_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038310","volume":"7","author":"JF Staropoli","year":"2012","unstructured":"Staropoli JF, Haliw L, Biswas S, Garrett L, Holter SM, Becker L et al (2012) Large-scale phenotyping of an accurate genetic mouse model of JNCL identifies novel early pathology outside the central nervous system. PLoS One 7(6):e38310. https:\/\/doi.org\/10.1371\/journal.pone.0038310","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"113_CR32","doi-asserted-by":"publisher","first-page":"s42","DOI":"10.1191\/0961203305LU2117OA","volume":"14","author":"P Vermersch","year":"2005","unstructured":"Vermersch P, Stojkovic T, de Seze J (2005) Mycophenolate mofetil and neurological diseases. Lupus 14(Suppl 1):s42\u2013s45","journal-title":"Lupus"},{"issue":"2","key":"113_CR33","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/0303-8467(82)90062-2","volume":"84","author":"IL Zweije-Hofman","year":"1982","unstructured":"Zweije-Hofman IL, van der Zee HJ, van Nieuwenhuizen O (1982) Anti-parkinson drugs in the Batten-Spielmeyer-Vogt syndrome; a pilot trial. Clin Neurol Neurosurg 84(2):101\u2013105","journal-title":"Clin Neurol Neurosurg"}],"container-title":["JIMD Reports","JIMD Reports, Volume 43"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/8904_2018_113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T17:13:43Z","timestamp":1571505223000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/8904_2018_113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9783662586136","9783662586143"],"references-count":33,"URL":"https:\/\/doi.org\/10.1007\/8904_2018_113","relation":{},"ISSN":["2192-8304","2192-8312"],"issn-type":[{"value":"2192-8304","type":"print"},{"value":"2192-8312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}